Werth V, Murrell D, Joly P, Ardeleanu M, Hultsch V
J Eur Acad Dermatol Venereol. 2024; 39(2):290-300.
PMID: 39297242
PMC: 11760689.
DOI: 10.1111/jdv.20313.
Le M, Khoury L, Lu Y, Prosty C, Cormier M, Cheng M
Open Forum Infect Dis. 2024; 11(4):ofae102.
PMID: 38560604
PMC: 10977629.
DOI: 10.1093/ofid/ofae102.
Balan R, Deleanu D, Pintea I, Dobrican Baruta C, Man M, Bocsan I
Biomedicines. 2023; 11(12).
PMID: 38137329
PMC: 10740468.
DOI: 10.3390/biomedicines11123108.
Park S, Kim Y, Lee G, Choi S
Sci Rep. 2023; 13(1):17607.
PMID: 37848636
PMC: 10582024.
DOI: 10.1038/s41598-023-44973-z.
Laidlaw T, White A
J Allergy Clin Immunol Pract. 2023; 12(1):79-84.
PMID: 37778627
PMC: 10842409.
DOI: 10.1016/j.jaip.2023.09.019.
Hypersensitivity reactions to biologics used in the treatment of allergic diseases: clinical features, diagnosis and management.
Sitek A, Chiarella S, Pongdee T
Front Allergy. 2023; 4:1219735.
PMID: 37637139
PMC: 10450930.
DOI: 10.3389/falgy.2023.1219735.
Long-Term Safety of Omalizumab in Children with Asthma and/or Chronic Spontaneous Urticaria: A 4-Year Prospective Study in Real Life.
Galletta F, Caminiti L, Lugara C, Foti Randazzese S, Barraco P, DAmico F
J Pers Med. 2023; 13(7).
PMID: 37511681
PMC: 10381149.
DOI: 10.3390/jpm13071068.
Current and Emerging Therapies for Chronic Spontaneous Urticaria: A Narrative Review.
Yosipovitch G, Soares G, Mahmoud O
Dermatol Ther (Heidelb). 2023; 13(8):1647-1660.
PMID: 37386330
PMC: 10366054.
DOI: 10.1007/s13555-023-00972-6.
Degranulation of Mast Cells as a Target for Drug Development.
Yang B, Kim A, Lee D, An S, Shim Y, Jang M
Cells. 2023; 12(11).
PMID: 37296626
PMC: 10253146.
DOI: 10.3390/cells12111506.
Risks and safety of biologics: A practical guide for allergists.
Sitek A, Li J, Pongdee T
World Allergy Organ J. 2023; 16(1):100737.
PMID: 36694621
PMC: 9853370.
DOI: 10.1016/j.waojou.2022.100737.
Therapeutical Targets in Allergic Inflammation.
Salvati L, Liotta F, Annunziato F, Cosmi L
Biomedicines. 2022; 10(11).
PMID: 36359393
PMC: 9687898.
DOI: 10.3390/biomedicines10112874.
Shifts in Asthma Evaluation and Management During COVID-19.
Lin C, Cerrone D
Curr Treat Options Allergy. 2022; 9(2):42-51.
PMID: 35582628
PMC: 9099326.
DOI: 10.1007/s40521-022-00304-7.
Anaphylaxis Associated With Allergen Specific Immunotherapy, Omalizumab, and Dupilumab: A Real World Study Based on the US Food and Drug Administration Adverse Event Reporting System.
Bian S, Zhang P, Li L, Wang Z, Cui L, Xu Y
Front Pharmacol. 2021; 12:767999.
PMID: 34744748
PMC: 8569862.
DOI: 10.3389/fphar.2021.767999.
Chronic Urticaria: Advances in Understanding of the Disease and Clinical Management.
He L, Yi W, Huang X, Long H, Lu Q
Clin Rev Allergy Immunol. 2021; 61(3):424-448.
PMID: 34529248
DOI: 10.1007/s12016-021-08886-x.
Anaphylactic risk related to omalizumab, benralizumab, reslizumab, mepolizumab, and dupilumab.
Li L, Wang Z, Cui L, Xu Y, Guan K, Zhao B
Clin Transl Allergy. 2021; 11(4):e12038.
PMID: 34123366
PMC: 8175040.
DOI: 10.1002/clt2.12038.
.
Bauer A, Dickel H, Jakob T, Kleinheinz A, Lippert U, Metz M
Allergo J. 2021; 30(2):40-55.
PMID: 33785991
PMC: 7994058.
DOI: 10.1007/s15007-021-4772-2.
Case Report: Mastocytosis: The Long Road to Diagnosis.
Rama T, Martins D, Gomes N, Pinheiro J, Nogueira A, Delgado L
Front Immunol. 2021; 12:635909.
PMID: 33643319
PMC: 7907169.
DOI: 10.3389/fimmu.2021.635909.
Anti-IgE for the Treatment of Chronic Urticaria.
Wedi B, Traidl S
Immunotargets Ther. 2021; 10:27-45.
PMID: 33628747
PMC: 7898214.
DOI: 10.2147/ITT.S261416.
Multicentre experience of home omalizumab treatment for chronic spontaneous urticaria.
Denman S, El-Shanaway T, Carne E, Devlin L, Savic S
Eur J Hosp Pharm. 2020; 27(6):367-368.
PMID: 33097621
PMC: 7856134.
DOI: 10.1136/ejhpharm-2019-001914.
Emerging Causes of Drug-Induced Anaphylaxis: A Review of Anaphylaxis-Associated Reports in the FDA Adverse Event Reporting System (FAERS).
Yu R, Krantz M, Phillips E, Stone Jr C
J Allergy Clin Immunol Pract. 2020; 9(2):819-829.e2.
PMID: 32992044
PMC: 7870524.
DOI: 10.1016/j.jaip.2020.09.021.
